Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

BIOTALYS Stock Was 23.75% Up Today

Loading stream...

(VIANEWS) - The Market ended the session with BIOTALYS (BTLS.BR) jumping 23.75% to €3.96 on Tuesday, after two sequential sessions in a row of losses. BEL 20 rose 0.6% to €3,742.59, after two sequential sessions in a row of losses, on what was a somewhat bullish trend trading session today.

About BIOTALYS

Biotalys NV, an agricultural technology company, discovers and develops novel biological products for the protection of food and crops. It primarily develops biofungicides, bioinsecticides, and biobactericides. The company was formerly known as Agrosavfe NV. Biotalys NV was incorporated in 2013 and is headquartered in Gent, Belgium.

Earnings Per Share

As for profitability, BIOTALYS has a trailing twelve months EPS of €-0.76.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOTALYS's stock is considered to be overbought (>=80).

More news about BIOTALYS (BTLS.BR).

Categories

stockMarket

Tags

Market-Close NowStock PriceClosesStock Market NowEnd of DayPrice UpMarket CloseStock Price UpStock MarketStockBIOTALYSBTLS.BR
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com